Infectious complications of chronic lymphocytic leukaemia: Pathogenesis, spectrum of infection, preventive approaches

Best Practice and Research: Clinical Haematology

Volumn 23, Issue 1, 2010, Pages 145-153

  Morrison, Vicki A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

alemtuzumab; fludarabine; hypogammaglobulinaemia; immunoglobulin; pentostatin; prophylaxis

Indexed keywords

ALEMTUZUMAB; ANTIVIRUS AGENT; BETA GLUCURONIDASE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIPHTHERIA VACCINE; FLUDARABINE; GANCICLOVIR; HAEMOPHILUS VACCINE; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN M; INFLUENZA VACCINE; INTERLEUKIN 2; INTERLEUKIN 4; MUMPS VACCINE; OBLIMERSEN; PENTOSTATIN; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; PREDNISONE; RITUXIMAB; TETANUS TOXOID; TYPHOID VACCINE; UNINDEXED DRUG; VALGANCICLOVIR; VARICELLA ZOSTER VACCINE;

ANTIBIOTIC PROPHYLAXIS; ANTIMICROBIAL THERAPY; ASPERGILLOSIS; ASPERGILLUS; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTERIAL INFECTION; CANDIDA; CANDIDIASIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; CYTOMEGALOVIRUS INFECTION; DIPHTHERIA; DISEASE PREDISPOSITION; EPSTEIN BARR VIRUS INFECTION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FEBRILE NEUTROPENIA; HAEMOPHILUS INFECTION; HAEMOPHILUS INFLUENZAE; HERPES VIRUS; HERPES VIRUS INFECTION; HERPES ZOSTER; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNOGLOBULIN A DEFICIENCY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN DEFICIENCY; IMMUNOGLOBULIN G DEFICIENCY; INFECTION COMPLICATION; INFECTION PREVENTION; INFECTION RISK; INFLUENZA; KIDNEY FAILURE; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LISTERIA; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; MUCOSAL IMMUNITY; MULTIPLE CYCLE TREATMENT; MUMPS; MYCOBACTERIUM; OPPORTUNISTIC INFECTION; PATHOGENESIS; PNEUMOCOCCAL INFECTION; PNEUMOCYSTIS; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; PYREXIA IDIOPATHICA; RECURRENT INFECTION; RESPIRATORY TRACT INFECTION; REVIEW; SEASONAL INFLUENZA; SIDE EFFECT; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; TETANUS; TYPHOID FEVER; URINARY TRACT INFECTION; VACCINATION; VARICELLA ZOSTER VIRUS; VIRUS INFECTION; VIRUS REACTIVATION;

ANTIBODIES, MONOCLONAL; HUMANS; INFECTION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; RISK FACTORS;

EID: 77956632397     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2009.12.004     Document Type: Review

References (70)

1. P. Wadhwa, and V.A. Morrison Infectious complications of chronic lymphocytic leukemia Semin Oncol 33 2006 240 249
2. F. Ravandi, and S. O'Brien Immune defects in patients with chronic lymphocytic leukemia Cancer Immunol Immunother 55 2006 197 209
3. J. Aittoniemi, A. Miettinen, and S. Laine Opsonising immunoglobulins and mannan-binding lectin in chronic lymphocytic leukemia Leuk Lymphoma 34 1999 381 385
4. V.A. Morrison, J.R. Hibbs, and E.N. Janoff Systemic and mucosal immunoglobulin levels and risk of infection in patients with chronic lymphocytic leukemia and multiple myeloma Blood 88 Suppl. 1 1996 240a (Abstract #948)
5. M. Sinisalo, J. Aittoniemi, and T. Koski Similar humoral immunity parameters in chronic lymphocytic leukemia patients independent of VH gene mutation status Leuk Lymphoma 45 2004 2451 2454
6. H gene mutation status and other prognostic factors on the incidence of major infections in patients with chronic lymphocytic leukemia Cancer 107 2006 1023 1033
7. K.R. Rai, B. Peterson, and F.R. Appelbaum Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia N Engl J Med 343 2000 1750 1757
8. S. O'Brien, H. Kantarjian, and M. Beran Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment Blood 2 1993 1695 1700
9. M.J. Keating, S. O'Brien, and H. Kantarjian Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent Blood 81 1993 2878 2884 (Pubitemid 23162104)
10. M.J. Keating, S.O. O'Brien, and S. Lerner Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy Blood 92 1998 1165 1171
11. E. Anaissie, D.P. Kontoyiannis, H. Kantarjian, L. Elting, L.E. Robertson, and M. Keating Listeriosis in patients with chronic lymphocytic leukemia who were treated with fludarabine and prednisone Ann Intern Med 117 1992 466 469
12. V.A. Morrison, K.R. Rai, and B. Peterson Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: intergroup study cancer and leukemia group B 9011 J Clin Oncol 19 2001 3611 3621
13. E.J. Anaissie, D.P. Kontoyiannis, and S. O'Brien Infections in patients with chronic lymphocytic leukemia treated with fludarabine Ann Intern Med 129 1998 559 566
14. D.A. Frank, S. Mahajan, and J. Ritz Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling Nat Med 5 1999 444 447
15. E. Morra, A. Nosari, and M. Montillo Infectious complications in chronic lymphocytic leukemia Hematol Cell Ther 41 1999 145 151
16. M. Hensel, M. Kornaker, and S. Yammeni Disease activity and pretreatment, rather than hypogammaglobulinemia, are major risk factors for infectious complications in patients with chronic lymphocytic leukemia Br J Haematol 122 2003 600 606
17. A. Molteni, A. Nosari, and M. Montillo Multiple lines of chemotherapy are the main risk factor for severe infections in patients with chronic lymphocytic leukemia with febrile episodes Haematol 90 2005 1145 1147
18. M. Leporrier, S. Chevret, and B. Cazin Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients Blood 98 2001 2319 2325
19. M. Steurer, G. Pall, and S. Richards Single-agent purine analogues for the treatment of chronic lymphocytic leukaemia: a systematic review and meta-analysis Cancer Treat Rev 32 2006 377 389
20. I.W. Flinn, J.C. Byrd, and C. Morrison Fludarabine and cyclophosphamide with filgrastim support in patients with previously untreated indolent lymphoid malignancies Blood 96 2000 71 75
21. I.W. Flinn, D. Neuberg, and M.R. Grever Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997 J Clin Oncol 25 2007 793 798
22. M. Hallek, B. Schmitt, and M. Wilhelm Fludarabine plus cyclophosphamide is an effective treatment for advanced chronic lymphocytic leukemia (CLL): Results of a phase II study of the German CLL Study Group Br J Haematol 114 2001 342 348
23. B.F. Eichhorst, R. Busch, and G. Hopfinger Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia Blood 107 2006 885 891
24. B.F. Eichhorst, R. Busch, and C. Schweighofer Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy Br J Haematol 136 2006 63 72
25. S. O'Brien, J.O. Moore, and T.E. Boyd Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia J Clin Oncol 25 2007 1114 1120
26. M. Kowal, A. Dmoszynska, and K. Lewandowski Efficacy and safety of fludarabine and cyclophosphamide combined therapy in patients with refractory/recurrent B-cell chronic lymphocytic leukaemia (B-CLL)-polish multicentre study Leuk Lymphoma 45 2004 1159 1165
27. P. Jindra, V. Koza, and L. Boudova Epstein-Barr virus-associated B-cell lymphoproliferative disorder in CLL patients after treatment with fludarabine and cyclophosphamide followed by high-dose chemotherapy with autologous stem cell transplantation Bone Marrow Transpl 31 2003 951 952
28. J.D. Hainsworth, S. Litchy, and J.H. Barton Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the minnie pearl cancer research network J Clin Oncol 21 2003 1746 1751
29. J.C. Byrd, B.L. Peterson, and V.A. Morrison Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from Cancer and leukemia group B 9712 (CALGB 9712) Blood 101 2003 6 14
30. M.J. Keating, S. O'Brien, and M. Albitar Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia J Clin Oncol 23 2005 4079 4088
31. W. Wierda, S. O'Brien, and S. Wen Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia J Clin Oncol 23 2005 4070 4078 (Pubitemid 46211312)
32. T. Robak, J.Z. Blonski, H. Urbanska-Rys, M. Blasinska-Morawiec, and A.B. Skotnicki 2-chlorodeoxyadenosine (cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger Leukemia 13 1999 518 523 (Pubitemid 29195278)
33. T. Robak, M. Blasinska-Morawiec, J.Z. Blonski, and A. Dmoszynska 2-chlorodeoxyadenosine (cladribine) in the treatment of elderly patients with B-cell chronic lymphocytic leukemia Leuk Lymphoma 34 1999 151 157 (Pubitemid 29248670)
34. J.C. Byrd, B. Peterson, and L. Piro A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB study 9211 Leukemia 17 2003 323 327
35. L.D. Piro, C.J. Carrera, E. Beutler, and D.A. Carson 2- chlorodeoxyadenosine: An effective new agent for the treatment of chronic lymphocytic leukemia Blood 72 1988 1069 1073
36. T. Robak, J.Z. Blonski, and M. Kasznicki Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukaemia - updated results of the multicentre study of 378 patients Br J Haematol 108 2000 357 368
37. T. Robak, J.Z. Blonski, and M. Kasznicki Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: report of a prospective, randomized, multicenter trial Blood 96 2000 2723 2729
38. R.O. Dillman, R. Mick, and O.R. McIntyre Pentostatin in chronic lymphocytic leukemia: A phase II trial of Cancer and Leukemia Group B J Clin Oncol 7 1989 433 438
39. M.M. Oken, S. Lee, and N.E. Kay Pentostatin, chlorambucil and prednisone therapy for B-chronic lymphocytic leukemia: a phase I/II study by the Eastern Cooperative Oncology Group study E1488 Leuk Lymphoma 45 2004 79 84
40. N. Lamanna, M. Kalaycio, and P. Maslak Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia J Clin Oncol 24 2006 1575 1581
41. T.D. Shanafelt, T. Lin, and S.M. Geyer Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia Cancer 109 2007 2291 2298
42. J. Lundin, A. Porwit-MacDonald, and E.D. Rossmann Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia Leukemia 18 2004 484 490
43. J. Lundin, and A. Osterborg Advances in the use of monoclonal antibodies in the therapy of chronic lymphocytic leukemia Semin Hematol 41 2004 234 245 (Pubitemid 38953166)
44. G. Lozanski, N.A. Heerema, and I.W. Flinn Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions Blood 103 2004 3278 3281
45. M.J. Keating, I. Flinn, and V. Jain Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study Blood 99 2002 3554 3561
46. K.R. Rai, C.E. Freter, and R.J. Mercier Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine J Clin Oncol 20 2002 3891 3897
47. J. Lundin, E. Kimby, and M. Bjorkholm Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL) Blood 100 2002 768 773
48. A. Cortelezzi, M.C. Pasquini, and B. Sarina A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with chemotherapy-refractory chronic lymphocytic leukemia Haematol 90 2005 410 412
49. S.I. Martin, F.M. Marty, and K. Fiumara Infectious complications associated with alemtuzumab use for lymphoproliferative disorders Clin Infect Dis 43 2006 16 24
50. P. Hillmen, A.B. Skotnicki, and T. Robak Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia J Clin Oncol 25 2007 5616 5623
51. S. Faderl, D.A. Thomas, and S. O'Brien Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies Blood 101 2003 3413 3415
52. T. Elter, P. Borchmann, and H. Schulz Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: Results of a phase II trial J Clin Oncol 23 2005 7024 7031
53. S. O'Brien, M.J. Keating, and E.S. Mocarski Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab Clin Lymphoma Myeloma 7 2006 125 130
54. S.M. O'Brien, H.M. Kantarjian, and D.A. Thomas Alemtuzumab as treatment for residual diseased after chemotherapy in patients with chronic lymphocytic leukemia Cancer 98 2003 2657 2663
55. C.M. Wendtner, M. Ritgen, and C.D. Schweighofer Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission-experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG) Leukemia 18 2004 1093 1101
56. K.R. Rai, J.C. Byrd, B.L. Peterson, and R.A. Larson A phase II trial of fludarabine followed by alemtuzumab in previously untreated chronic lymphocytic leukemia (CLL) patients with active disease: cancer and leukemia Group B (CALGB) study 19901 Blood 100 2002 205a 206a
57. K.R. Rai, J.C. Byrd, and B.L. Peterson Subcutaneous alemtuzumab following fludarabine for previously untreated patients with chronic lymphocytic leukemia (CLL): CALGB study 19901 Blood 102 2003 676
58. M. Montillo, A.M. Cafro, and A. Tedeschi Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine Haematologica 87 2002 695 700
59. V.A. Morrison, B.L. Peterson, and K.R. Rai Alemtuzumab increases serious infections in patients with previously untreated chronic lymphocytic leukemia (CLL) receiving fludarabine-based therapy: A comparative analysis of 3 Cancer and Leukemia Group B Studies (CALGB 9011, 9712, 19901) Blood 110 2007 233
60. T. Lin, K.A. Donohue, and M.S. Lucas Consolidation therapy with subcutaneous (SC) alemtuzumab results in serious infectious toxicity in previously untreated CLL patients who achieve a complete remission (CR) after fludarabine and rituximab (FR) induction therapy: Interim safety analysis of the CALGB study 10101 Blood 110 2007 232 233
61. L. Shvidel, M. Shtalrid, and O. Bairey Conventional dose fludarabine-based regimens are effective but have excessive toxicity in elderly patients with refractory chronic lymphocytic leukemia Leuk Lymphoma 44 2003 1947 1950
62. V.A. Morrison, J.C. Byrd, and B.L. Peterson Adding rituximab to fludarabine therapy for patients with untreated chronic lymphocytic leukemia (CLL) does not increase the risk of infection: cancer and leukemia group B (CALGB) study Blood 102 2003 440a
63. L. Laurenti, P. Piccioni, and P. Cattani Cytomegalovirus reactivation during alemtuzumab therapy for chronic lymphocytic leukemia: incidence and treatment with oral ganciclovir Haematol 89 2004 1248 1252
64. T.F. Smith, M.J. Espy, and J. Mandrekar Quantitative real-time polymerase chain reaction for evaluating DNAemia due to cytomegalovirus, Epstein-Barr virus, and BK virus in solid-organ transplant recipients Clin Infect Dis 45 2007 1056 1061
65. S. O'Brien, F. Ravandi-Kashani, and W.G. Wierda A randomized trial of valacyclovir versus valganciclovir to prevent CMV reactivation in patients with CLL receiving alemtuzumab Blood 106 2005 830a
66. Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia N Engl J Med 319 1988 902 907
67. S. Molica, P. Musto, and F. Chiurazzu Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. results of a crossover study Haematologica 81 1996 121 126
68. M. Sinisalo, J. Aittoniemi, and H. Kayhty Vaccination against infections in chronic lymphocytic leukemia Leuk Lymphoma 44 2003 649 652
69. A. Hartkamp, A.H. Mulder, and G.T. Rijkers Antibody responses to pneumococcal and haemophilus vaccinations in patients with B-cell chronic lymphocytic leukaemia Vaccine 19 2001 1671 1677
70. M. Sinisalo, J. Aittoniemi, and P. Oivanen Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia Br J Haematol 114 2001 107 110